logo
The Buzbee Law Firm Urges National Push for Corporate Accountability

The Buzbee Law Firm Urges National Push for Corporate Accountability

Globe and Mail2 days ago
Texas firm behind $640M verdict says real change starts with citizen action and jury service
The Buzbee Law Firm, a nationally recognized litigation firm based in Texas, is calling on citizens, business leaders, and jurors to take a more active role in holding corporations accountable for negligence and misconduct. In a newly featured article titled 'How Landmark Verdicts Like the $640M Loree Case Are Reshaping Corporate Accountability in America,' the firm reflects on the implications of the historic wrongful death verdict they secured earlier this year—and what it means for everyday people.
'When a jury delivers a $640 million verdict, it's not just about compensation—it's about consequences,' a firm representative said. 'It's about signaling that companies can't ignore safety without facing serious repercussions.'
The firm's message is clear: meaningful accountability starts in communities—not just in courtrooms, but in workplaces, homes, and on juries.
A Wake-Up Call for Corporate America
The Loree v. TNT Crane & Rigging case captured national attention when a Houston jury awarded $640 million—including $480 million in punitive damages—after David Lester Loree II was killed during a crane operation. The defendant's initial settlement offer was just $6.9 million. The jury's decision sent a powerful message.
'The jury didn't just want to make the family whole,' The Buzbee Law Firm stated. 'They wanted to tell every company watching: if you cut corners and someone gets hurt, you will be held accountable.'
According to the National Center for State Courts, civil juries now return verdicts in favor of plaintiffs nearly 60% of the time in workplace injury and wrongful death cases—up from 52% just a few years ago. Meanwhile, the average jury award in these cases has increased 40% since 2015.
What You Can Do Right Now
The Buzbee Law Firm isn't asking for donations or proposing legislation. Instead, they are encouraging everyday Americans to take five simple actions that can drive systemic change:
Serve When Called: 'Jury duty isn't a burden—it's a responsibility. Jurors are the last line of defense when corporations fail the public.'
Speak Up in the Workplace: Identify and report unsafe conditions. Encourage transparency and accountability at every level.
Vote for Oversight: Elect officials who prioritize consumer safety and corporate regulation.
Support Transparency: Elevate stories of corporate misconduct and legal reform. Awareness breeds action.
Audit Internally: Business leaders should review safety protocols and training now—before a verdict forces their hand.
'You don't need to be in a courtroom to protect your community,' the firm noted. 'You just need to care enough to act—wherever you are.'
Making Negligence Too Expensive to Ignore
The firm believes large verdicts like the one in Loree are key to real change—not because they destroy companies, but because they force decision-makers to rethink how they measure risk.
'After a major verdict, we often see companies overhaul training programs, replace leadership, and install new safety systems,' The Buzbee Law Firm said. 'Not because they want to—but because they have to.'
A Texas Case with National Consequences
The Loree verdict is already influencing how corporations and attorneys approach risk management and trial strategy nationwide. But for The Buzbee Law Firm, the broader takeaway is about community power.
'This case wasn't just about Texas. It was about what happens when ordinary people—jurors, workers, voters—demand better. That's how real accountability begins.'
To read more, visit the website here.
About The Buzbee Law Firm
The Buzbee Law Firm is a Houston-based trial firm with a national reputation for high-impact litigation. With billions recovered in verdicts and settlements, the firm handles cases involving catastrophic injury, commercial disputes, and corporate negligence. They are dedicated to protecting the public and holding powerful entities accountable.
Contact:
info@tonybuzbeephilanthropy.com
Media Contact
Company Name: The Buzbee Law Firm
Contact Person: Tony Buzbee
Email: Send Email
Country: United States
Website: https://www.tonybuzbeephilanthropy.com/
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Dividend Stocks to Buy for Decades of Passive Income
2 Dividend Stocks to Buy for Decades of Passive Income

Globe and Mail

time3 hours ago

  • Globe and Mail

2 Dividend Stocks to Buy for Decades of Passive Income

Key Points Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits for a long time to come. That's thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon. These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVie AbbVie is a pharmaceutical leader with a large portfolio of approved products, none more important than a duo of immunology medicines: Skyrizi and Rinvoq. In the first quarter, the company's revenue increased by 8.4% year over year to $13.3 billion, while its adjusted earnings per share came in at $2.46, 6.5% higher than the year-ago period. These results are all the more impressive considering AbbVie faced a major patent cliff just two years ago; however, it has since recovered, largely thanks to Skyrizi and Rinvoq. The former generated $3.4 billion in sales during the period, representing a 70.5% year-over-year increase. Rinvoq's revenue came in at $1.7 billion, 57.2% higher than the year-ago period. Management predicts their combined annual sales will exceed $31 billion by 2027. Not only is that significantly higher than the $17.7 billion they racked up last year, it's also $4 billion higher than their previous guidance. Skyrizi and Rinvoq are expected to drive top-line growth well into the 2030s. Although they will eventually lose patent protection, they demonstrate AbbVie's ability to navigate even the biggest patent cliffs, a quality that is essential for any pharmaceutical company to thrive over the long term. AbbVie has other products that help drive revenue growth, and, equally important, it has a deep pipeline that it routinely strengthens through acquisitions. In March, the company announced a licensing deal with Denmark-based Gubra A/S for GUB014295, an investigational weight management therapy. AbbVie paid $350 million up front for this candidate, with potential milestones of $1.9 billion, not including royalties. AbbVie entered the fast-growing weight loss market with this move; GUB014295 might not pan out, but AbbVie's large pipeline, with approximately 90 products in development, should allow it to launch brand-new products frequently, navigate patent cliffs, and remain successful over the long run. Now turning to the company's dividend, AbbVie has increased its payouts by 310% since 2013. And counting the time it spent under Abbott Laboratories' name, AbbVie is a Dividend King with 53 consecutive years of payout increases. These facts, from AbbVie's underlying business to the company's dividend track record, point to a company capable of sustaining a passive income program for a long time. 2. Abbott Laboratories Abbott Laboratories is best known for its leadership in the medical device space, where it markets dozens of products across multiple therapeutic areas. The company also operates a diagnostic business and has a presence in the pharmaceutical and nutrition industries. Abbott Laboratories' operations are diversified, which can help it overcome challenges in specific segments. That's one of the company's strengths. Here's another: Abbott Laboratories has been a leader in the highly regulated healthcare sector for decades. The company has built a solid reputation with physicians and consumers, all of whom are more likely to gravitate toward the brands they know and trust. In the medical device field, Abbott is a trusted brand. And thanks to its vast portfolio, it generates consistent revenue and earnings. Abbott's biggest growth driver in recent years has been its diabetes care segment, led by its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. As the company noted, the FreeStyle Libre has become the most successful medical device in history in terms of dollar sales. That's no small feat. Yet there is still massive whitespace ahead, since only a small portion of the world's diabetics use CGM technology despite its advantages. Abbott's work in this niche should provide a powerful long-term tailwind, but there will be many others. The company boasts other growth drivers, including its structural heart segment, where it markets a range of successful devices, such as its MitraClip device, a leader in its mitral valve repair niche. Beyond any single product, Abbott Laboratories has a proven track record as an innovator and should continue launching newer and better ones. Lastly, Abbott is also a Dividend King, and over the past decade, it has increased its payouts by almost 146%. Abbott Laboratories' business is built to last. Investors who purchase the company's shares today can expect consistent dividend growth over the long term. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025

Elon Musk announces new 'America Party' after Trump's massive spending bill becomes law
Elon Musk announces new 'America Party' after Trump's massive spending bill becomes law

CBC

time4 hours ago

  • CBC

Elon Musk announces new 'America Party' after Trump's massive spending bill becomes law

The dispute between U.S. Republican President Donald Trump and his main campaign financier Elon Musk took another fractious turn on Saturday when the space and automotive billionaire announced the formation of a new political party, saying Trump's "big, beautiful" tax bill would bankrupt America. A day after asking his followers on his X platform whether a new U.S. political party should be created, Musk declared in a post on Saturday: "Today, the America Party is formed to give you back your freedom." "By a factor of 2 to 1, you want a new political party and you shall have it!" he wrote. The announcement from Musk comes after Trump signed his self-styled "big, beautiful" tax-cut and spending bill into law on Friday, which Musk fiercely opposed. WATCH | What drove a wedge between Trump and Musk: Will Donald Trump and Elon Musk destroy each other? 25 days ago Duration 25:36 Musk, who became the word's richest man thanks to his Tesla car company and his SpaceX satellite firm, spent hundreds of millions on Trump's re-election and led the Department of Government Efficiency, aimed at slashing government spending, from the start of the president's second term. The first sign of investor dissatisfaction with Musk's announcement followed later in the day. Investment firm Azoria Partners will postpone the listing of a Tesla exchange-traded fund, Azoria CEO James Fishback said in a post on X. Fishback is asking Tesla's board to clarify Musk's political ambitions and said the new party undermines the confidence shareholders had that he would be focusing more on the company after leaving government service in May. Musk said previously that he would start a new political party and spend money to unseat lawmakers who supported the bill. Trump earlier this week threatened to cut off the billions of dollars in subsidies that Musk's companies receive from the federal government. Republicans have expressed concern that Musk's on-again, off-again feud with Trump could hurt their chances to protect their majority in the 2026 midterm congressional elections. Asked on X what was the one thing that made him go from loving Trump to attacking him, Musk said: "Increasing the deficit from an already insane $2T under Biden to $2.5T. This will bankrupt the country." There was no immediate comment from Trump or the White House on Musk's announcement. The feud with Trump, often described as one between the world's richest man and the world's most powerful, has led to several precipitous falls in Tesla's share price. The stock soared after Trump's November re-election and hit a high of more than $488 US in December, before losing more than half of its value in April and closing out last week at $315.35 US. Despite Musk's deep pockets, breaking the Republican-Democratic duopoly will be a tall order, given that it has dominated American political life for more than 160 years, while Trump's approval ratings in polls in his second term have generally held firm above 40 per cent, despite often divisive policies.

Trump's ‘reciprocal' tariff pause is about to expire. Cue the confusion
Trump's ‘reciprocal' tariff pause is about to expire. Cue the confusion

CTV News

time4 hours ago

  • CTV News

Trump's ‘reciprocal' tariff pause is about to expire. Cue the confusion

The 90-day deadline U.S. President Donald Trump set for countries to make trade deals with the United States or risk substantially higher tariffs is just days away. What will happen after that's reached at 12:01 a.m. ET on July 9 is anyone's best guess. The stakes could not be higher, with the entire global economy on notice. On April 2, a date Trump dubbed 'Liberation Day,' he unveiled new, 'reciprocal' tariff rates for key US trading partners, with some levies as high as 50 per cent. Collectively, the rates were the highest the US has charged on foreign goods in over a century. Economists quickly sounded alarms about a recession hitting not just certain countries, but rather the whole world. As the tariffs went into effect on April 9, they sparked a sell-off on Wall Street and the bond market rebelled, forcing Trump to announce a three-month pause to give countries more time to solidify deals with the US, saying investors 'were getting a little bit yippy, a little afraid.' Since then, almost all goods the US imports have been subject to a minimum 10 per cent tariff. Stocks, meanwhile, have not only recovered all those losses but have set multiple new record highs. And inflation has barely budged. But if tariffs start to rise again and inflation roars back, those gains could quickly get erased all over again. After months of meeting with foreign government officials and countless claims that several trading partners were on the cusp of completing deals, only three have been announced. One of those, with Vietnam, has yet to be finalized and few details are known about it. Still, the Trump administration is advertising that a flurry of deals are forthcoming. At the same time, the president has threatened to send letters to countries that don't ink deals, telling them the rate at which their exports to the US will be taxed. Leading up to July 9, Trump administration officials threatened to simply return to April tariff rates, or possibly even higher levies. They also floated the possibility of extending the pause for countries 'negotiating in good faith,' without defining what that means or which it includes. It's not clear where Trump, who will get the ultimate say, stands. 'We can do whatever we want. We could extend it; we could make it shorter,' Trump recently said. 'I'd like to make it shorter. I'd like to just sent letters out to everybody, 'Congratulations, you're paying 25 per cent.'' 'We'll look at how a country treats us — are they good, are they not so good — some countries we don't care, we'll just send a high number out,' Trump also recently said. On Friday, he said he'd begin sending letters over the coming days. 'They'll range in value from maybe 60 per cent or 70 per cent tariffs to 10 per cent and 20 per cent tariffs,' Trump said. For many countries, such rates would deal an even bigger economic blow compared to the levels Trump announced in April. But countries may have the opportunity to still negotiate, given Trump said most new rates won't take effect until August 1. America's evolving pain tolerance for higher tariffs The deal Trump announced on Wednesday with Vietnam, which calls for minimum tariffs of 20 per cent on Vietnamese goods, double the rate throughout the three-month pause, has raised the possibility that countries may not be able to score lower rates even if they reach a trade agreement. But considering tariffs on Vietnam were set to rise to a minimum of 46 per cent if the rates Trump announced in April held — which was among the highest Trump announced — 20 per cent suddenly feels like a relief. That may be an intentional strategy on Trump's part, allowing him to stick to his major campaign promise of levying higher tariffs on other nations in an effort to raise revenues and bring manufacturing jobs back to the US. 'On balance, we take the U.S.-Vietnam accord as a positive step toward more durable bilateral deals for the US and toward greater clarity for investors,' Ulrike Hoffmann-Burchardi, global head of equities at UBS Global Wealth Management, said in a note last week. 'Headline risks around trade may persist as negotiations continue, but we think the market impact should moderate as President Trump's negotiating tactics become increasingly familiar,' he said. 'Ultimately, we expect the US administration to prioritize economic stability over more maximalist tariffs, especially ahead of the 2026 midterm elections.' Elisabeth Buchwald, CNN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store